Headache Drugs Logo
Home | About Dr. Robbins | Archived Articles | Headache Books | Topic Index  

Back to List



Duration of Migraine is a Predictor for
Response to Botulinum Toxin Type A
Eross EJ; Gladstone JP; Lewis S; et al.
Posted: May 2005  
Headache 2005;45:308-314

Objective:   To identify the clinical characteristics and/or injection parameters that predict a favorable response to botulinum toxin type A (BoNT-A) in patients with episodic and chronic migraine.

Methods:  We conducted a prospective, open-label study on 74 patients from our clinic receiving BoNT-A for episodic or chronic migraine. For all patients, migraine-related disability, headache frequency, and average headache intensity were obtained at baseline and at 3 months post BoNT-A. Information regarding demographic characteristics and injection parameters was also collected.

Conclusion:  BoNT-A may be effective in decreasing headache frequency, headache intensity, and headache-related disability in episodic and chronic migraine patients. Duration of illness emerged as a predictor of treatment response. Randomized controlled studies should evaluate headache-related disability as a primary endpoint in patients with episodic and chronic headache.